- Home
- PBFS vs CDXS Comparison
PBFS vs CDXS Comparison
Compare PBFS & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- CDXS
- Stock Information
- Founded
- PBFS 1889
- CDXS 2002
- Country
- PBFS United States
- CDXS United States
- Employees
- PBFS N/A
- CDXS N/A
- Industry
- PBFS Banks
- CDXS Major Chemicals
- Sector
- PBFS Finance
- CDXS Industrials
- Exchange
- PBFS Nasdaq
- CDXS Nasdaq
- Market Cap
- PBFS 302.3M
- CDXS 254.3M
- IPO Year
- PBFS N/A
- CDXS 2010
- Fundamental
- Price
- PBFS $12.41
- CDXS $2.77
- Analyst Decision
- PBFS
- CDXS Buy
- Analyst Count
- PBFS 0
- CDXS 2
- Target Price
- PBFS N/A
- CDXS $11.00
- AVG Volume (30 Days)
- PBFS 24.9K
- CDXS 765.5K
- Earning Date
- PBFS 09-24-2025
- CDXS 08-13-2025
- Dividend Yield
- PBFS N/A
- CDXS N/A
- EPS Growth
- PBFS 50.26
- CDXS N/A
- EPS
- PBFS 0.91
- CDXS N/A
- Revenue
- PBFS $91,369,000.00
- CDXS $49,815,000.00
- Revenue This Year
- PBFS N/A
- CDXS $12.53
- Revenue Next Year
- PBFS N/A
- CDXS $22.54
- P/E Ratio
- PBFS $13.59
- CDXS N/A
- Revenue Growth
- PBFS 23.15
- CDXS N/A
- 52 Week Low
- PBFS $10.07
- CDXS $1.90
- 52 Week High
- PBFS $12.65
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- PBFS 55.69
- CDXS 48.32
- Support Level
- PBFS $12.30
- CDXS $2.58
- Resistance Level
- PBFS $12.47
- CDXS $2.96
- Average True Range (ATR)
- PBFS 0.22
- CDXS 0.18
- MACD
- PBFS -0.01
- CDXS -0.04
- Stochastic Oscillator
- PBFS 62.50
- CDXS 23.46
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.